Nanomaterials from the hybrid of organic and inorganic materials for the treatment of cancer
build significant value in our nanomaterial drug candidates that address unmet medical needs
We aspire to substantially improve health care using our nanotechnology platforms
PDX Pharmaceuticals, LLC, has an office in Lake Oswego, Oregon, and a laboratory on the 13th floor of the OHSU’s Center for Health and Healing in Portland, Oregon. The company utilize the state of the art equipment at the Biomedical…
RNA Interference (RNAi). Recent advances in genetic sequencing are beginning to shed light on functionally redundant genes which drive cancer development. RNA interference circumvents the druggability issue associated with…
Our nanoparticle carrier platform is a hybrid of polymer coating and inorganic nanoparticle core, which takes full advantage of both materials to overcome siRNA delivery barriers such as short bl
PDX Pharmaceuticals, LLC, is a discovery stage therapeutics company with a focus on developing functionalized nanomaterials into drugs. We aspire to substantially improve health care using our nanotechnology platforms. To focus on the translation of our research, a limited liability company “PDX Pharmaceuticals, LLC” was established in 2010, supported by the Biomedical Engineering Department of Oregon Health and Science University (OHSU) School of Medicine and The Oregon Nanoscience and Microtechnologies Institute (ONAMI). PDX Pharmaceuticals was established with the express intent to in-license and reduce-to-practice the founder’s inventions that are currently or will be assigned to parent institutions, OHSU (current) and the Pacific Northwest National Laboratory (PNNL) (previous). Of present focus are novel nanomaterials from the hybrid of organic and inorganic materials for the treatment of cancer (breast, prostate, and pancreatic cancer), fibrosis, and hyperphosphatemia.
The Company’s strategy is to build significant value in our nanomaterial drug candidates that address unmet medical need and have substantial commercial potential, secure intellectual property rights, and initiate early stage commercial development (e.g., pre-clinical and toxicity evaluations, as well as Phase I clinical trials by partnering with OHSU). Upon sufficient validation of our candidates, the Company intends to partner with one or more large pharmaceutical companies that have substantial experience and background in clinical trial execution, manufacturing expertise, and existing distribution channels for such therapies.
Our technology has been developed through significant support from NIH (NCI, NIDDK, NIGMS, NIEHS, NIAID), ONAMI, OHSU, PNNL, and angel funds.